HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) will have CEO Andrew Simpson present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023, scheduled for April 25-27, 2023, at the Horseshoe Hotel & Casino in Las Vegas.
The presentation is set for April 26, 2023, at 11:00 AM Pacific Time. The event will also allow for one-on-one meetings with Mr. Simpson. HeartSciences focuses on enhancing the diagnostic capacity of Electrocardiograms (ECGs) using AI technology. Their key product candidate, MyoVista®, aims to provide insights into cardiac dysfunction traditionally accessed only through cardiac imaging, aiming to make ECGs a more effective screening tool.
The company leverages a proprietary business model centered around its MyoVista® device, which is expected to generate recurring revenue through consumable electrodes.
- None.
- None.
Southlake, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today announces that CEO Andrew Simpson will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023.
The conference is being held on April 25 – 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally’s) in Las Vegas, NV.
Presentation Date: April 26, 2023
Time: 11:00am Pacific Time
Webcast Link: https://www.webcaster4.com/Webcast/Page/2963/47983
Mr. Simpson will be available for one-on-one meetings at the conference venue. To request a meeting and to register for the conference, click here: https://planetmicrocapshowcase.com/signup
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Millions of ECGs are performed every week and the Company’s objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista® device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista® are proprietary to HeartSciences, and new electrodes are required for every test performed. For more information, please visit: https://www.heartsciences.com.
Twitter: @HeartSciences
For Investor and Media Inquiries, please contact:
Investor Relations
CoreIR
Email: scottg@coreir.com
Tel: 631-703-4900
Website: www.coreir.com
Company
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: investorrelations@heartsciences.com
FAQ
What is the date of Andrew Simpson's presentation at VEGAS 2023?
Where is the Planet MicroCap Showcase: VEGAS 2023 being held?
What is the focus of HeartSciences' technology?
What is the MyoVista® device developed by HeartSciences?
How does the MyoVista® business model work?
